InterCure (NASDAQ:INCR) Trading 1.5% Higher – Still a Buy?

Posted by Sarita Garza on Aug 5th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) shares were up 1.5% during mid-day trading on Monday . The stock traded as high as $0.9999 and last traded at $0.9760. Approximately 8,424 shares traded hands during trading, a decline of 57% from the average session volume of 19,470 shares. The stock had previously closed at $0.9618.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Research Report on InterCure

InterCure Price Performance

The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48. The stock has a market capitalization of $52.04 million, a price-to-earnings ratio of 31.72 and a beta of 1.40. The business’s 50 day simple moving average is $0.98 and its 200-day simple moving average is $0.89.

InterCure Company Profile

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.